Cargando…

Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients

BACKGROUND: In the last decade, it has become clear that change of gene expression may alter the hematopoietic cell quiescent state and consequently play a major role in leukemogenesis. WT1 is known to be a player in acute myeloid leukemia (AML) and FOXP3 has a crucial role in regulating the immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Assem, Magda M, Osman, Ahmed, Kandeel, Eman Z, Elshimy, Reham A A, Nassar, Hanan R, Ali, Radwa E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454620/
https://www.ncbi.nlm.nih.gov/pubmed/27893200
http://dx.doi.org/10.22034/APJCP.2016.17.10.4699
_version_ 1783240861904011264
author Assem, Magda M
Osman, Ahmed
Kandeel, Eman Z
Elshimy, Reham A A
Nassar, Hanan R
Ali, Radwa E
author_facet Assem, Magda M
Osman, Ahmed
Kandeel, Eman Z
Elshimy, Reham A A
Nassar, Hanan R
Ali, Radwa E
author_sort Assem, Magda M
collection PubMed
description BACKGROUND: In the last decade, it has become clear that change of gene expression may alter the hematopoietic cell quiescent state and consequently play a major role in leukemogenesis. WT1 is known to be a player in acute myeloid leukemia (AML) and FOXP3 has a crucial role in regulating the immune response. OBJECTIVES: To evaluate the impact of overexpression of WT1and FOXP3 genes on clinical course in adult and pediatric AML patients in Egypt. PATIENTS AND METHODS: Bone marrow and peripheral blood samples were obtained from 97 de novo non M3 AML patients (63 adult and 34 pediatric). Real-time quantitative PCR was used to detect overexpression WT1 and FOXP3 genes. Patient follow up ranged from 0.2 to 39.0 months with a median of 5 months. RESULTS: In the pediatric group; WT1 was significantly expressed with a high total leukocyte count median 50X109/L (p=0.018). In the adult group, WT1 had an adverse impact on complete remission induction, disease-free survival and overall survival (p=0.02, p=0.035, p=0.019 respectively). FOXP3 overexpression was associated with FAB subtypes AML M0 +M1 vs. M2, M4+M5 (p =0.039) and the presence of hepatomegaly (p=0.005). CONCLUSIONS: WT1 and FOXP3 overexpression has an adverse impact on clinical presentation, treatment response and survival of pediatric and adult Egyptian AML patients.
format Online
Article
Text
id pubmed-5454620
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-54546202017-08-28 Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients Assem, Magda M Osman, Ahmed Kandeel, Eman Z Elshimy, Reham A A Nassar, Hanan R Ali, Radwa E Asian Pac J Cancer Prev Research Article BACKGROUND: In the last decade, it has become clear that change of gene expression may alter the hematopoietic cell quiescent state and consequently play a major role in leukemogenesis. WT1 is known to be a player in acute myeloid leukemia (AML) and FOXP3 has a crucial role in regulating the immune response. OBJECTIVES: To evaluate the impact of overexpression of WT1and FOXP3 genes on clinical course in adult and pediatric AML patients in Egypt. PATIENTS AND METHODS: Bone marrow and peripheral blood samples were obtained from 97 de novo non M3 AML patients (63 adult and 34 pediatric). Real-time quantitative PCR was used to detect overexpression WT1 and FOXP3 genes. Patient follow up ranged from 0.2 to 39.0 months with a median of 5 months. RESULTS: In the pediatric group; WT1 was significantly expressed with a high total leukocyte count median 50X109/L (p=0.018). In the adult group, WT1 had an adverse impact on complete remission induction, disease-free survival and overall survival (p=0.02, p=0.035, p=0.019 respectively). FOXP3 overexpression was associated with FAB subtypes AML M0 +M1 vs. M2, M4+M5 (p =0.039) and the presence of hepatomegaly (p=0.005). CONCLUSIONS: WT1 and FOXP3 overexpression has an adverse impact on clinical presentation, treatment response and survival of pediatric and adult Egyptian AML patients. West Asia Organization for Cancer Prevention 2016 /pmc/articles/PMC5454620/ /pubmed/27893200 http://dx.doi.org/10.22034/APJCP.2016.17.10.4699 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Assem, Magda M
Osman, Ahmed
Kandeel, Eman Z
Elshimy, Reham A A
Nassar, Hanan R
Ali, Radwa E
Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients
title Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients
title_full Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients
title_fullStr Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients
title_full_unstemmed Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients
title_short Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients
title_sort clinical impact of overexpression of foxp3 and wt1 on disease outcome in egyptian acute myeloid leukemia patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454620/
https://www.ncbi.nlm.nih.gov/pubmed/27893200
http://dx.doi.org/10.22034/APJCP.2016.17.10.4699
work_keys_str_mv AT assemmagdam clinicalimpactofoverexpressionoffoxp3andwt1ondiseaseoutcomeinegyptianacutemyeloidleukemiapatients
AT osmanahmed clinicalimpactofoverexpressionoffoxp3andwt1ondiseaseoutcomeinegyptianacutemyeloidleukemiapatients
AT kandeelemanz clinicalimpactofoverexpressionoffoxp3andwt1ondiseaseoutcomeinegyptianacutemyeloidleukemiapatients
AT elshimyrehamaa clinicalimpactofoverexpressionoffoxp3andwt1ondiseaseoutcomeinegyptianacutemyeloidleukemiapatients
AT nassarhananr clinicalimpactofoverexpressionoffoxp3andwt1ondiseaseoutcomeinegyptianacutemyeloidleukemiapatients
AT aliradwae clinicalimpactofoverexpressionoffoxp3andwt1ondiseaseoutcomeinegyptianacutemyeloidleukemiapatients